Natixis Advisors LLC increased its stake in The Walt Disney Company (NYSE:DIS) by 2.4% in the fourth quarter, purchasing an additional 49,195 shares. This brings their total holding to 2,120,702 shares valued at approximately $241.3 million. Institutional investors collectively own 65.71% of Disney's stock, with several other funds also reporting minor increases in their positions. The article notes positive sentiment for Disney due to brand visibility, live-action adaptations, park investments, and strong gaming performance, while analyst ratings are a "Moderate Buy" with a target price of $134.47.

Natixis Advisors LLC reduced its stake in The Home Depot, Inc. (NYSE:HD) by 12% in the fourth quarter of last year, selling over 111,000 shares. This move leaves the firm with 817,843 shares, currently valued at approximately $281.4 million. Despite this reduction by one institutional investor, Home Depot recently reported better-than-expected quarterly earnings and declared a quarterly dividend of $2.33 per share, while analysts generally maintain a "Moderate Buy" consensus rating with an average price target of $371.39.

Invitation Homes Inc. (US46187W1071) is preparing to present at Nareit’s REITweek 2026 investor conference, with its NYSE-listed shares trading around USD 29. The company's management will discuss its portfolio, operating performance, and balance sheet positioning, highlighting strong first-quarter 2026 results and positive rental market fundamentals. This presentation is expected to influence investor sentiment regarding the single-family rental REIT’s valuation and growth strategy.

Thompson Siegel & Walmsley LLC has invested $4.40 million in Best Buy Co., Inc. by acquiring 65,700 shares. This comes as Best Buy reported better-than-expected quarterly results, driven by strong AI laptop demand and gaming sales, and confirmed its fiscal 2027 outlook, including a quarterly dividend of $0.96 per share. Despite positive financial news and institutional investment, analysts maintain a cautious "Hold" rating with an average price target of $78.60 for the stock.

Natixis Advisors LLC has increased its stake in Ross Stores, Inc. by 8.6% in the fourth quarter, bringing its total holding to over 1.1 million shares worth approximately $213.5 million. This coincides with positive analyst sentiment, with many raising price targets and maintaining "Buy" or better ratings, resulting in a consensus target price of $233.18. Ross Stores recently posted strong quarterly results, exceeding EPS and revenue expectations, and announced a quarterly dividend.

Palo Alto Networks has finalized its acquisition of Portkey, an AI production firm. Portkey's technology will integrate with Palo Alto Networks' Prisma AIRS platform, functioning as an AI gateway to secure AI interactions and enforce governance policies. This acquisition aims to allow organizations to adopt AI capabilities safely and efficiently within their core business operations.

Vantus Wealth LLC has acquired 9,754 shares of Walmart Inc. (NASDAQ:WMT) for approximately $1.09 million, making it their 29th-largest holding and representing 0.8% of their portfolio. This purchase reflects continued strong institutional interest in Walmart, despite some insider selling. The company's business momentum is being driven by digital expansion, including drone deliveries and expanded 30-minute delivery services, leading to generally positive analyst ratings and raised price targets.

Ascendiant Capital has maintained a 'Buy' rating on Genasys (GNSS) and increased its price target from $5.50 to $6.00, indicating a positive outlook for the stock. Despite this, GuruFocus assesses GNSS as undervalued with a GF Value™ of $3.41 against a current price of $2.12, but also notes an average GF Score™ of 51/100, driven by low financial strength and growth metrics, suggesting a potential "value trap." Investors are advised to exercise caution and thoroughly evaluate risks.

Fulcrum Therapeutics' stock plummeted by 48% after the company announced it would discontinue pociredir, its lead drug candidate for sickle cell disease. The decision leaves Fulcrum Therapeutics with no products on the market, despite its efforts to commercialize the experimental drug. The company cited "no viable path forward" for the sickle cell treatment.

Verizon has extended the early participation date for its private exchange offers and consent solicitations for 11 series of notes to June 16, 2026. As of June 1, 2026, early tenders for these notes ranged from 0.96% to 85.89% of the principal outstanding across different series. The new notes will have the same economic terms as the old notes but will initially be unregistered, with participation limited to qualified institutional buyers and non-U.S. qualified investors.